Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 J+Natl+Compr+Canc+Netw 2015 ; 13 (3): 261-72 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Myelodysplastic Syndromes, Version 2 2015: Featured Updates to the NCCN Guidelines #MMPMID25736003
Greenberg PL; Stone RM; Bejar R; Bennett JM; Bloomfield CD; Borate U; De Castro CM; Deeg HJ; DeZern AE; Fathi AT; Frankfurt O; Gaensler K; Garcia-Manero G; Griffiths EA; Head D; Klimek V; Komrokji R; Kujawski LA; Maness LJ; O?Donnell MR; Pollyea DA; Scott B; Shami PJ; Stein BL; Westervelt P; Wheeler B; Shead DA; Smith C
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.